|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1703.80
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | UnAudited | Net Sales | 41,157.50 | 36,592.30 | 34,956.40 | 28,362.70 | Total Expenditure | 28,984.10 | 28,239.90 | 27,906.20 | 25,740.90 | PBIDT (Excl OI) | 12,173.40 | 8,352.40 | 7,050.20 | 2,621.80 | Other Income | 231.60 | 256.00 | 277.40 | 553.00 | Operating Profit | 12,405.00 | 8,608.40 | 7,327.60 | 3,174.80 | Interest | 113.60 | 153.20 | 161.80 | 294.40 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 12,291.40 | 8,455.20 | 7,165.80 | 2,880.40 | Depreciation | 1,451.80 | 1,494.80 | 1,400.50 | 1,462.00 | Profit Before Tax | 10,839.60 | 6,960.40 | 5,765.30 | 1,418.40 | Tax | 1,675.20 | 1,474.30 | 995.70 | 228.30 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 9,164.40 | 5,486.10 | 4,769.60 | 1,190.10 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 9,164.40 | 5,486.10 | 4,769.60 | 1,190.10 | Equity Capital | 910.70 | 910.50 | 910.20 | 910.00 | Face Value (IN RS) | 2 | 2 | 2 | 2 | Reserves | | | | | Calculated EPS | 20.13 | 12.05 | 10.48 | 2.62 | Calculated EPS (Annualised) | 80.50 | 48.20 | 41.92 | 10.46 | No of Public Share Holdings | 241,121,806.00 | 241,017,240.00 | 240,877,544.00 | 240,781,686.00 | % of Public Share Holdings | 52.96 | 52.94 | 52.93 | 52.92 | | | | | | PBIDTM% (Excl OI) | 29.58 | 22.83 | 20.17 | 9.24 | PBIDTM% | 30.14 | 23.53 | 20.96 | 11.19 | PBDTM% | 29.86 | 23.11 | 20.50 | 10.16 | PBTM% | 26.34 | 19.02 | 16.49 | 5.00 | PATM% | 22.27 | 14.99 | 13.64 | 4.20 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|